Tumor suppressor candidate 3 is a protein that in humans is encoded by the TUSC3gene.[1][2][3]
This gene is a candidate tumor suppressor gene. It is located within a homozygously deleted region of a metastatic prostate cancer. The gene is expressed in most nonlymphoid human tissues including prostate, lung, liver, and colon. Expression was also detected in many epithelial tumor cell lines. Two transcript variants encoding distinct isoforms have been identified for this gene.[3]
References
↑MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R (Sep 1996). "Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22". Genomics. 35 (1): 55–65. doi:10.1006/geno.1996.0322. PMID8661104.
Pak BJ, Park H, Chang ER, et al. (1998). "Differential display analysis of oxygen-mediated changes in gene expression in first trimester human trophoblast cells". Placenta. 19 (7): 483–8. doi:10.1016/S0143-4004(98)91041-4. PMID9778121.
Kelleher DJ, Karaoglu D, Mandon EC, Gilmore R (2003). "Oligosaccharyltransferase isoforms that contain different catalytic STT3 subunits have distinct enzymatic properties". Mol. Cell. 12 (1): 101–11. doi:10.1016/S1097-2765(03)00243-0. PMID12887896.
Anderson NL, Polanski M, Pieper R, et al. (2004). "The human plasma proteome: a nonredundant list developed by combination of four separate sources". Mol. Cell. Proteomics. 3 (4): 311–26. doi:10.1074/mcp.M300127-MCP200. PMID14718574.
Shibatani T, David LL, McCormack AL, et al. (2005). "Proteomic analysis of mammalian oligosaccharyltransferase reveals multiple subcomplexes that contain Sec61, TRAP, and two potential new subunits". Biochemistry. 44 (16): 5982–92. doi:10.1021/bi047328f. PMID15835887.
Rual JF, Venkatesan K, Hao T, et al. (2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature. 437 (7062): 1173–8. doi:10.1038/nature04209. PMID16189514.
Pils D, Horak P, Gleiss A, et al. (2006). "Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival". Cancer. 104 (11): 2417–29. doi:10.1002/cncr.21538. PMID16270321.
Guervós MA, Marcos CA, Hermsen M, et al. (2007). "Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas". Cell. Oncol. 29 (4): 327–34. PMID17641416.